A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis or localised disease with poor histological response).
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Mifamurtide (Primary) ; Cisplatin; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms SARCOME13
- 03 Oct 2018 Planned End Date changed from 1 Aug 2028 to 1 Oct 2028.
- 03 Oct 2018 Planned primary completion date changed from 1 Aug 2022 to 1 Oct 2022.
- 03 Oct 2018 Status changed from not yet recruiting to recruiting.